NCT05445349

Breathing Parameter Measurements for Lung Deposition Simulation

Measurement of Breathing Parameters of Asthma and COPD Patients With Different Degrees of Disease Severity for the Computer Simulation of Lung Deposition of Aerosol Drugs
Medisol Development Kft.·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Asthma,COPD
Drug/Device/Intervention
Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Medisol Development Kft.
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2022
End date
Jun 30, 2025
Enrollment
200 participants
Primary outcome

Lung deposition fraction

Summary

This study aims to simulate the deposition of aerosol drugs within the airways of asthma and
 COPD patients based on realistic breathing patterns measured at different pulmonology
 centers.
 
 Further goal of the study is to find correlations between the amount of drug depositing in
 the lungs and the measured breathing parameters, as well as disease status and demographic
 data. The results of the study will be part of a major objective targeting the optimization
 and personalization of aerosol drug therapy.

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaOther chronic obstructive pulmonary disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05445349
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05445349 through Pure Global AI's free database. This phase not specified trial is sponsored by Medisol Development Kft. and is currently Not yet recruiting. The study focuses on Asthma,COPD. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.